About Aptadel Therapeutics
Aptadel Therapeutics is a company based in Barcelona (Spain) founded in 2020 by Oscar Martínez Tirado. It operates as a B2B. Aptadel Therapeutics offers products and services including RNA Aptamer Technology. Aptadel Therapeutics operates in a competitive market with competitors including SpringWorks Therapeutics, QSAM Biosciences, Vuja De Sciences, ECM Therapeutics and Atlanthera, among others.
- Headquarter Barcelona, Spain
- Founders Oscar Martínez Tirado
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aptadel Therapeutics
Aptadel Therapeutics offers a comprehensive portfolio of products and services, including RNA Aptamer Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tool for delivering therapeutics like siRNA into cancer cells
Unlock access to complete
Unlock access to complete
Funding Insights of Aptadel Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Aptadel Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aptadel Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aptadel Therapeutics Comparisons
Competitors of Aptadel Therapeutics
Aptadel Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SpringWorks Therapeutics, QSAM Biosciences, Vuja De Sciences, ECM Therapeutics and Atlanthera, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for cancer and rare diseases.
|
|
| domain | founded_year | HQ Location |
Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation
|
|
| domain | founded_year | HQ Location |
Therapies for preventing cancer metastasis and recurrence are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic and therapeutic products from extracellular matrix are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for bone diseases and tumors are developed.
|
|
| domain | founded_year | HQ Location |
Nanomedicine platform for targeted bone drug delivery is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Aptadel Therapeutics
When was Aptadel Therapeutics founded?
Aptadel Therapeutics was founded in 2020.
Where is Aptadel Therapeutics located?
Aptadel Therapeutics is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
What does Aptadel Therapeutics do?
Aptadel Therapeutics is a biotech company that creates RNA Aptamer technologies to deliver therapeutics into cancer cells, focusing on conditions like Ewing Sarcoma. As a pre-clinical stage firm, it customizes tools for siRNA, miRNA, and other agents across oncology indications. The company, a spin-off from IDIBELL and co-founded by Fundación Alba, operates from Barcelona, Spain, aiming to advance treatments through research and partnerships.
Who are the top competitors of Aptadel Therapeutics?
Aptadel Therapeutics's top competitors include SpringWorks Therapeutics, Vuja De Sciences and QSAM Biosciences.
What products or services does Aptadel Therapeutics offer?
Aptadel Therapeutics offers RNA Aptamer Technology.